Stockreport

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Teva Pharmaceutical Industries Limited American Depositary Shares  (TEVA) 
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm Check Earnings Report
US:NYSE Investor Relations: ir.tevapharm.com
PDF New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different dosesNew endpoints pre [Read more]